Geron Corporation (NASDAQ: GERN) saw its stock surge 8.70% in pre-market trading on Wednesday following the release of its better-than-expected third-quarter 2025 results and improved financial guidance for the year. The hematology drug developer's performance was primarily driven by strong sales of its flagship product, RYTELO.

For the third quarter of 2025, Geron reported net product revenue of $47.167 million from RYTELO sales, despite a 3% decline in demand. The company's operating loss narrowed to $13.887 million, significantly beating analyst expectations of a $17.3 million loss. Net loss for the quarter also improved to $18.428 million, compared to $26.4 million in the same period last year.

Adding to the positive sentiment, Geron revised its fiscal year 2025 outlook, now expecting total operating expenses to be between $250 million and $260 million, down from the previously announced guidance of $270 million to $285 million. This reduction in projected expenses, coupled with anticipated RYTELO sales, has bolstered investor confidence in the company's financial position. Geron stated that it believes its existing resources and RYTELO sales will be sufficient to fund future operations for the foreseeable future. The company also anticipates an interim analysis of its IMpactMF study in the second half of 2026, potentially providing another catalyst for growth.